Genotype frequencies of <i>BCL2</i> among case and control subjects and their associations with risk of lung cancer.

<p>Note: Associations were determined for haplotypes >5% frequency.</p>*<p>Data were calculated by unconditional logistic regression models, adjusted for age, smoking status, pack-year smoked, and family history of cancer.</p>†<p>Polymorphic bases were in the order of rs2279115 C>A, rs1801018 A>G, rs1564483 G>A from 5′ to 3′. Frequencies of haplotypes were determined using THESIAS v3.1 software.</p

Genotype and haplotype analysis of <i>BCL2</i> with overall survival of male advance NSCLC patients.

<p>Abbreviations: MST, median survival time; HR, hazard ratio.</p><p>Note: The frequency of rs1564483GG genotype was 0.8% (2/242), so we combined rs1564483AG with GG genotype for analyses. Survival analyses were determined for haplotypes or diplotypes >5% frequency.</p>*<p>Cox regression analysis was adjusted for age, smoking status, histology, TNM stage, surgery, chemotherapy, and radiotherapy status.</p>†<p>Polymorphic bases were in the order of rs2279115 C>A, rs1801018A>G, rs1564483G>A from 5′ to 3′. Frequencies of haplotypes were determined using THESIAS v3.1 software.</p

General information of case patients and control subjects.

*<p>Two-sided chi-square test.</p>†<p>Others include large cell, bronchioalveolar, mixed cell, undifferentiated and pathologic not otherwise specified carcinomas.</p

Stratification analysis for associations between <i>BCL2</i> rs1564483 (c*1204G>A) genotypes and risk of lung cancer.

<p>Note: ORs and <i>P</i> values were obtained from logistic regression models with adjustment for age, smoking status, pack-year smoked, and family history of cancer.</p

Patient characteristics and clinical features.

<p>Abbreviations: MST, median survival time; SCC, Squamous cell carcinoma; HR, hazard ratio.</p>*<p>Data were calculated by univariate cox regression analysis.</p>†<p>Others include large cell, bronchioalveolar, mixed cell, undifferentiated and pathologic not otherwise specified carcinomas.</p

Kaplan-Meier survival curve for male advanced NSCLC patients by <i>BCL2</i> rs1564483 G>A genotypes.

<p>Kaplan-Meier survival curve for male advanced NSCLC patients by <i>BCL2</i> rs1564483 G>A genotypes.</p